AR051431A1 - Compuestos de pirazolina substituidos, su preparacion y su uso como medicamentos - Google Patents

Compuestos de pirazolina substituidos, su preparacion y su uso como medicamentos

Info

Publication number
AR051431A1
AR051431A1 ARP050100550A ARP050100550A AR051431A1 AR 051431 A1 AR051431 A1 AR 051431A1 AR P050100550 A ARP050100550 A AR P050100550A AR P050100550 A ARP050100550 A AR P050100550A AR 051431 A1 AR051431 A1 AR 051431A1
Authority
AR
Argentina
Prior art keywords
mono
substituted
optionally
group
saturated
Prior art date
Application number
ARP050100550A
Other languages
English (en)
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR051431A1 publication Critical patent/AR051431A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)

Abstract

Métodos para su preparacion, a medicamentos que comprenden estos compuestos así como a su uso para la preparacion de un medicamento para el tratamiento de seres humanos y animales. Reivindicacion 1: Compuestos de pirazolina sustituidos de formula general (1), en la que: R1 representa un grupo fenilo opcionalmente al menos mono-sustituido, R2 representa un grupo fenilo opcionalmente al menos mono-sustituido; R3 representa un grupo cicloalifático que contiene opcionalmente al menos un heteroátomo como miembro del anillo, opcionalmente al menos mono-sustituido, saturado o insaturado, que puede esta condensado con un sistema de anillo mono- o policíclico opcionalmente al menos mono-sustituido, o R3 representa un grupo arilo o heteroarilo opcionalmente al menos mono-sustituido, que puede estar condensado con un sistema de anillo mono- o policíclico opcionalmente al menos mono-sustituido, o R3 representa un resto -NR4R5-; R4 y R5, idénticos o diferentes, representan un átomo de hidrogeno, un radical alifático opcionalmente al menos mono-sustituido, no ramificado o ramificado, saturado o insaturado, un grupo cicloalifático que contiene opcionalmente al menos un heteroátomo como miembro del anillo, opcionalmente al menos mono-sustituido, saturado o insaturado, que puede estar condensado con un sistema de anillo mono- o policíclico opcionalmente al menos mono-sustituido, o un grupo arilo o heteroarilo opcionalmente al menos mono-sustituido, que puede estar condensado con un sistema de anillo mono- o policíclico opcionalmente al menos mono-sustituido y/o unido a través de un grupo alquileno lineal o ramificado, un resto -SO2-R6- o resto -NR7R8; con las condiciones de que: R4 y R5 no representan a la vez un átomo de hidrogeno; y si uno de los restos R4 y R5 representa un átomo de hidrogeno o un grupo alquilo, que está opcionalmente al menos mono-sustituido con un grupo alcoxi, un grupo alcoxialcoxi, un átomo de halogeno o un grupo fenilo, el otro de estos restos R4 y R5 no represente un grupo pirid-2-ilo, que está opcionalmente mono-sustituido en la posicion 5, un grupo pirid-5-ilo, que está opcionalmente mono-sustituido en la posicion 2, un grupo pirimid-5-ilo, que está opcionalmente mono-sustituido en la posicion 2, un grupo piridaz-3-ilo, que está opcionalmente mono-sustituido en la posicion 6, un grupo pirazin-5-ilo, que está opcionalmente mono-sustituido en la posicion 2, un grupo tien-2-ilo, que está opcionalmente mono- sustituido en la posicion 5, un grupo tien-2-ilo, que está opcionalmente al menos mono-sustituido en la posicion 4, un grupo bencilo, que está opcionalmente mono-sustituido en la posicion 4 del anillo, un grupo fenetilo, que está opcionalmente mono- sustituido en la posicion 4 del anillo, un grupo fenilo opcionalmente mono-, di- o tri-sustituido, un grupo fenilo di-sustituido, donde los dos sustituyentes juntos forman una cadena -OCH2O-, -OCH2CH2O- o -CH2CH2O-, que está opcionalmente sustituido con uno o más átomos de halogeno o uno o dos grupos metilo, un resto -NH-fenilo, donde el grupo fenilo puede estar mono-sustituido en la posicion 4; y si uno de los restos R4 y R5 representan un grupo alquinilo, el otro de estos restos R4 y R5 no represente un grupo fenilo, que está opcionalmente sustituido en la posicion 4, y si uno de los restos R4 y R5 representa un átomo de hidrogeno o un radical alifático lineal o ramificado, saturado o insaturado, sustituido o no sustituido, el otro de estos restos R4 y R5 no represente un grupo tiazol sustituido o no sustituido o un grupo [1,3,4]tiadiazol sustituido o no sustituido; R6 representa un grupo alifático lineal o ramificado, saturado o insaturado, opcionalmente al menos mono- sustituido, un grupo cicloalifático que opcionalmente contiene al menos un heteroátomo como miembro del anillo, saturado o insaturado, opcionalmente al menos mono-sustituido, que puede estar condensado con un sistema de anillo mono- o policíclico, o un grupo arilo o heteroarilo opcionalmente al menos mono-sustituido, que puede estar condensado con un sistema de anillo mono- o policíclico y/o unido a través de un grupo alquileno lineal o ramificado; R7 y R8, idénticos o diferentes, representan un átomo de hidrogeno, un radical alifático ramificado o no ramificado, saturado o insaturado, opcionalmente al menos mono-sustituido, un grupo cicloalifático que contiene opcionalmente al menos un heteroátomo como miembro del anillo, saturado o insaturado, opcionalmente al menos mono-sustituido, que puede estar condensado con un sistema de anillo mono- o policíclico opcionalmente al menos mono-sustituido, o un grupo arilo o heteroarilo opcionalmente al menos mono-sustituido, que puede estar condensado con un sistema de anillo mono- o policíclico opcionalmente al menos mono-sustituido y/o unido a través de un grupo alquileno lineal o ramificado; opcionalmente e forma de uno de los estereoisomeros, preferiblemente enantiomeros o diastereomeros, un racemato o en forma de una mezcla de al menos dos de los estereoisomeros, preferiblemente enantiomeros y/o diastereomeros, en cualquier proporcion de mezcla, o un N-oxido correspondiente de los mismos, una sal correspondiente de los mismos, o un solvato correspondiente de los mismos.
ARP050100550A 2004-02-17 2005-02-16 Compuestos de pirazolina substituidos, su preparacion y su uso como medicamentos AR051431A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400378 2004-02-17
US80453404A 2004-03-19 2004-03-19

Publications (1)

Publication Number Publication Date
AR051431A1 true AR051431A1 (es) 2007-01-17

Family

ID=34863168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100550A AR051431A1 (es) 2004-02-17 2005-02-16 Compuestos de pirazolina substituidos, su preparacion y su uso como medicamentos

Country Status (18)

Country Link
US (3) US20080015198A1 (es)
EP (1) EP1626963B1 (es)
JP (2) JP2007507471A (es)
KR (1) KR20060129055A (es)
AR (1) AR051431A1 (es)
AU (1) AU2005212836A1 (es)
BR (1) BRPI0507755A (es)
CA (1) CA2556400A1 (es)
ES (1) ES2392058T3 (es)
IL (1) IL177450A0 (es)
MY (1) MY140826A (es)
NO (1) NO20064041L (es)
PE (1) PE20051140A1 (es)
RU (1) RU2006133262A (es)
SG (1) SG135192A1 (es)
TW (1) TW200533657A (es)
UY (1) UY28757A1 (es)
WO (1) WO2005077911A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745476B2 (en) * 2004-01-30 2010-06-29 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1749525A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti-addictive agent
EP1760078A1 (en) * 2005-07-15 2007-03-07 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds; methods for their preparation
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1749820A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salts of substituted pyrazoline compounds, their preparation and use as medicaments
EP1745782A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Use of substitued pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome
WO2007009692A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
EP1749821A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments
ES2326725B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
EP1849775A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Cycloalkane-substituted pyrazoline compounds, their preparation and use as medicaments
EP1757588A1 (en) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Polymorph of N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and its use as a cannabinoid receptor modulator
WO2007131538A1 (en) * 2005-07-15 2007-11-22 Laboratorios Del Dr. Esteve, S.A. Azepane- or azocane-substituted pyrazoline compounds, their preparation and use as medicaments
EP1745781A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combination of pyrazoline type cannabinoid receptor antagonist and statin
EP1849776A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
ES2326723B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazol sustituidos y combinaciones de los mismos para el tratamiento del sindrome metabolico.
ES2327203B1 (es) * 2005-07-15 2010-06-07 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos relacionados con la coagulacion.
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1749819A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. (rac)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrates
ES2323403B1 (es) * 2005-07-15 2010-04-19 Laboratorios Del Dr.Esteve, S.A. Uso de compuestos de pirazolina sustituidos para la preparacion de medicamentos pediatricos.
WO2007009687A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Carbonyl substituted pyrazoline compounds, their preparation and use as cb1 receptor modulators
EP1743637A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007009691A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent
ES2326461B1 (es) * 2005-07-15 2010-04-19 Laboratorios Del Dr. Esteve, S.A. Polimorfo de n-priperidinil-5-(4-clorofenil)-1-(2,4-dicloforenil)-4,5-dihidro-1h-pirazol-3-carboxamida y su uso como modulador de receptores de cannabinoides.
ES2326952B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Hidratos de (rac) -n-piperidinil-5-(4-clorofenil)-1-(2,4-diclorofenil)4,5-dihidro-1h-pirazol-3-carboxamida.
EP1743888A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators
WO2007009698A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Combination of pyrazoline type cannabinoid receptor antagonist and statin
ES2325722B1 (es) * 2005-07-15 2010-04-19 Laboratorios Del Dr.Esteve, S.A. Uso de compuestos de pirazolina sustituidos para la preparacion de medicamentos para el tratamiento del sindrome metabolico.
ES2327379B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
EP1743640A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the preparation of paediatric medicaments
EP1757587A1 (en) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
ES2327204B1 (es) * 2005-07-15 2010-06-07 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina octahidropentalensustituidos, su preparacion y su uso como medicamentos.
EP1743641A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
WO2007009709A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A. Cycloalkane-substituted pyrazoline compounds, their preparation and use as medicaments
ES2326460B1 (es) * 2005-07-15 2010-04-19 Laboratorios Del Dr. Esteve, S.A. Sales de amonio cuaternario de compuestos de pirazolina sustituidos, su preparacion y uso como medicamentos.
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1849783A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Octahydropentalene-substituted pyrazoline compounds, their preparation and use as medicaments
US7829581B2 (en) 2005-07-15 2010-11-09 Laboratorios Del Dr. Esteve, S.A. Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2007009710A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds: methods for their preparation
US7897589B2 (en) * 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743639A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
WO2007009682A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Oral pharmaceutical formulations comprising substituted pyrazoline compounds
ES2348374B1 (es) * 2005-07-15 2011-08-02 Laboratorios Del Dr Esteve, S.A. Formulaciones farmaceuticas orales que comprenden compuestos de pirazolina sustituidos.
AU2006328483A1 (en) * 2005-12-20 2007-06-28 Solvay Pharmaceuticals B.V. 4,5-dihydro- (1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
WO2008062424A2 (en) * 2006-07-31 2008-05-29 Cadila Healthcare Limited Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
EP1911747A1 (en) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
AR063497A1 (es) * 2006-10-23 2009-01-28 Lilly Co Eli Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
EP1946777A1 (en) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline for preventing weight gain
EP1944294A1 (en) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Gamma-polymorph of a substituted pyrazoline, its preparation and use as medicaments
EP1944293A1 (en) * 2007-01-15 2008-07-16 Laboratorios del Dr. Esteve S.A. Alpha-Polymorph of a substituted pyrazoline, its preparation and use as medicaments
EP1946778A1 (en) * 2007-01-16 2008-07-23 Laboratorios del Dr. Esteve S.A. Active substance combination for the treatment of diabetes
ES2328653B1 (es) * 2007-01-15 2010-05-28 Laboratorios Del Dr. Esteve S.A. Combinacion de sustancias activas para el tratamiento de la diabetes.
ES2330071B1 (es) * 2007-01-15 2010-07-05 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas.
EP1947089A1 (en) * 2007-01-18 2008-07-23 Laboratorios del Dr. Esteve S.A. A-polymorph of a substituted pyrazoline, its preparation and use as medicaments
AU2008300631A1 (en) 2007-09-20 2009-03-26 Abbott Healthcare Products B.V. 5-aryl-4,5-dihydro-(1H)-pyrazoles as cannabinoid CB1
EP2042175A1 (en) * 2007-09-21 2009-04-01 Laboratorios del Dr. Esteve S.A. Dose regimens of CB1-Receptor ligands in the treatment of obesity
EP2108643A1 (en) 2008-04-10 2009-10-14 Laboratorios Del. Dr. Esteve, S.A. 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist
PL2280961T3 (pl) * 2008-04-22 2012-12-31 Lilly Co Eli Związki 1,5-difenylo-pirolidyn-2-onu jako ligandy CB-1
EA201071222A1 (ru) * 2008-04-22 2011-12-30 Эли Лилли Энд Компани Соединения 1,5-дифенилпирролидин-2-она в качестве лигандов cb-1
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
EP3429997A1 (de) 2016-03-16 2019-01-23 Bayer CropScience Aktiengesellschaft N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel
CN110467605B (zh) * 2018-05-11 2022-07-29 南京大学 一类新型三芳基吡唑啉衍生物的制备方法及其在抗癌药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053661B (it) 1966-09-27 1981-10-10 Farmacosmici S P A Ammidi dell acido 3 5 metil 5 3 pirazol carbossilico
DE3540934A1 (de) 1985-11-19 1987-05-27 Bayer Ag Verwendung von pyrazolidindionen, neue pyrazolidindione und deren verwendung
EP0330678B1 (en) 1987-01-05 1990-10-24 E.I. Du Pont De Nemours And Company Insecticidal pyrazolines
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
WO1990003369A1 (en) * 1988-09-27 1990-04-05 E.I. Du Pont De Nemours And Company N-sulfenylated and n-acylated pyrazolines
JPH02117605A (ja) * 1988-10-26 1990-05-02 Nippon Nohyaku Co Ltd 白蟻防除剤及びその使用方法
JPH05503696A (ja) * 1990-01-31 1993-06-17 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 殺節足動物性ピラゾリン類、ピラゾリジン類およびヒドラジン類
EP0543930A1 (en) * 1990-08-17 1993-06-02 E.I. Du Pont De Nemours And Company Arthropodicidal pyrazolines, pyrazolidines and hydrazines
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2742147B1 (fr) * 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
EP1023066A4 (en) * 1997-06-13 2001-05-23 Smithkline Beecham Corp NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND
ES2130079B1 (es) * 1997-07-10 2000-01-16 Esteve Labor Dr Resolucion de aminas
ES2130083B1 (es) * 1997-08-04 2000-01-16 Esteve Labor Dr Procedimiento para la obtencion de los enantiomeros de cizolirtina.
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
US6291476B1 (en) * 1999-05-12 2001-09-18 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
AU771668C (en) 1999-06-16 2005-08-11 Temple University - Of The Commonwealth System Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
JP2004500401A (ja) 2000-03-23 2004-01-08 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体
CA2411585A1 (en) * 2000-06-22 2001-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
RU2272030C2 (ru) * 2000-08-01 2006-03-20 Оно Фармасьютикал Ко., Лтд. Производные 3,4-дигидроизохинолина и фармацевтический агент, включающий его в качестве активного ингредиента
ES2174757B1 (es) 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
US6635216B2 (en) * 2001-05-18 2003-10-21 Graham Engineering Corporation Blow molding machine and method
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
DE10143561B4 (de) * 2001-09-05 2011-12-15 Eads Deutschland Gmbh Verfahren und System zur Lokalisierung von Emittern
HUP0401567A3 (en) * 2001-09-21 2005-06-28 Solvay Pharm Bv Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
KR100501949B1 (ko) * 2001-11-06 2005-07-18 재단법인서울대학교산학협력재단 동기된 의사위성을 이용한 정밀 항법시스템
WO2003064389A1 (fr) * 2002-01-31 2003-08-07 Ono Pharmaceutical Co., Ltd. Composes bicycliques contenant de l'azote et medicaments contenant ces composes en tant qu'ingredient actif
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
FR2839718B1 (fr) * 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
BR0313743A (pt) * 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
SE0300010D0 (sv) * 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
US20060172019A1 (en) * 2003-03-07 2006-08-03 Ralston Stuart H Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
US7745476B2 (en) * 2004-01-30 2010-06-29 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
PT1713475E (pt) * 2004-01-30 2008-11-10 Solvay Pharm Bv Derivados de 4,5-diidro-1h-pirazol 1,3,5-trissubstituído tendo atividade antagonística a cb1
ES2238923B1 (es) * 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
KR20060135815A (ko) * 2004-02-17 2006-12-29 라보라토리오스 델 드라. 에스테브.에스.에이. 혈중 트리글리세리드를 감소시키기 위한 치환된 피라졸린화합물
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
JP4232703B2 (ja) * 2004-07-13 2009-03-04 ヤマハ株式会社 ディジタルミキサ装置
WO2006044556A2 (en) * 2004-10-14 2006-04-27 Galileo Pharmaceuticals, Inc. Dual inhibitors of lipoxygenase for treating diabetes
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
AR052559A1 (es) 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
AU2006207322A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1757587A1 (en) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US7897589B2 (en) * 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments

Also Published As

Publication number Publication date
JP2009137976A (ja) 2009-06-25
EP1626963A1 (en) 2006-02-22
ES2392058T3 (es) 2012-12-04
BRPI0507755A (pt) 2007-07-10
EP1626963B1 (en) 2012-08-15
NO20064041L (no) 2006-09-08
SG135192A1 (en) 2007-09-28
PE20051140A1 (es) 2006-04-05
IL177450A0 (en) 2006-12-10
UY28757A1 (es) 2005-10-31
TW200533657A (en) 2005-10-16
JP2007507471A (ja) 2007-03-29
WO2005077911A1 (en) 2005-08-25
AU2005212836A1 (en) 2005-08-25
CA2556400A1 (en) 2005-08-25
US20060189658A1 (en) 2006-08-24
US20060020010A1 (en) 2006-01-26
KR20060129055A (ko) 2006-12-14
RU2006133262A (ru) 2008-04-10
US20080015198A1 (en) 2008-01-17
MY140826A (en) 2010-01-29
US7524868B2 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
AR051431A1 (es) Compuestos de pirazolina substituidos, su preparacion y su uso como medicamentos
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR066543A1 (es) Derivados de piridazinona
AR097431A1 (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
PE20190653A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR055772A1 (es) Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
AR045387A1 (es) Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR058362A1 (es) Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos
AR056986A1 (es) Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
ECSP12011695A (es) Derivados de (tio) morfolina como moduladores de s1p
AR089568A1 (es) Compuestos heterociclicos y sus metodos de usos
ECSP056115A (es) ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA
AR105544A1 (es) Compuestos de n-carboxamida cíclica útiles como herbicidas
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
BRPI1016232A2 (pt) Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
AR065863A1 (es) Derivados de imidazolidinona
AR062737A1 (es) Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR089889A1 (es) Compuestos fungicidas de pirimidina
AR050341A1 (es) Compuestos derivados de piperidina, composicion farmaceutica en base al compuesto y su uso para preparar medicamentos

Legal Events

Date Code Title Description
FB Suspension of granting procedure